Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | PDE2A | O00408 | 6/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.42 |
| ▸ | HRH1 | P35367 | 2/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL434632 | 0.89 | PDE2A (0.46) | PDE2A | |
| SCHEMBL20217195 | 0.79 | SMYD3 (0.49) | — | |
| SCHEMBL948775 | 0.77 | PDE2A (0.47) | SLC6A2SLC6A4PDE2A | |
| SCHEMBL4236603 | 0.76 | HTR2C (0.53) | HTR2CSLC6A2SLC6A4PDE2AHRH3 | |
| SCHEMBL4236604 | 0.76 | HTR2C (0.53) | HTR2CSLC6A2SLC6A4PDE2AHRH3 | |
| SCHEMBL3660818 | 0.74 | SLC6A2 (0.58) | HTR2CSLC6A2SLC6A4 | |
| SCHEMBL382534 | 0.74 | HPGD (0.41) | HTR2CSLC6A2SLC6A4 | |
| SCHEMBL14787805 | 0.73 | AKT1S1 (0.51) | HTR2CSLC6A2SLC6A4HRH3HRH1 | |
| Formic Acid SCHEMBL21381877 | 0.72 | SLC6A2 (0.47) | HTR2CSLC6A2SLC6A4HRH3HRH1 | |
| SCHEMBL4028129 | 0.72 | TACR1 (0.38) | PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096524-B2 | Anthelmintic agents and their use | INTERVET INTERNATIONAL B.V. (NL) | 2015-08-04 | — | — | US | disclosed |
| EP-2408742-B1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INT BV (NL) | 2014-09-03 | — | — | EP | disclosed |
| EP-2234973-B1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INT BV (NL) | 2014-07-02 | — | — | EP | disclosed |
| US-8569495-B2 | Anthelmintic agents and their use | INTERVET INTERNATIONAL B.V. (NL) | 2013-10-29 | — | — | US | disclosed |
| EP-2408742-A1 | ANTHELMINTIC AGENTS AND THEIR USE | Intervet International B.V. (NL) | 2012-01-25 | — | — | EP | disclosed |
| US-20110319393-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2011-12-29 | — | — | US | disclosed |
| US-20110021506-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2011-01-27 | — | — | US | disclosed |
| WO-2010115688-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2010-10-14 | — | — | WO | disclosed |
| EP-2234973-A1 | ANTHELMINTIC AGENTS AND THEIR USE | Intervet International B.V. (NL) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009077527-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021506-A1 | ANTHELMINTIC AGENTS AND THEIR USE | ACHE, ABCB11, MPO | HTR2C 3378/4885SLC6A2 2453/4885SLC6A4 2026/4885 |
| US-20110319393-A1 | ANTHELMINTIC AGENTS AND THEIR USE | ACHE, ABCB11, MPO | HTR2C 3378/4885SLC6A2 2453/4885SLC6A4 2026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.